Vitae's Vagueness On Psoriasis Program Spooks Investors

Decision to end enrollment prematurely of Phase IIa proof-of-concept study apparently has led investors to assume safety issues for the first-in-class ROR gamma T inhibitor.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America